The anti-leukemic activity of DDA was independent of cytogenetic or molecular AML subtypes and prominent in CD34+CD38−CD123+ AML cells, indicating a broad potential for this compound in the therapy of AML patients. Here, CD34 is linked to acute myeloid leukemia.